Hyperbaric Oxygen Therapy for Post-Concussion Syndrome: What to Know

A concussion that was supposed to resolve in a week or two instead leaves behind headaches, dizziness, a persistent mental fog, and a new sensitivity to bright light or background noise. Weeks turn into months, and the symptoms do not fully lift. This lingering pattern is known as post-concussion syndrome, and it is one of the more frustrating outcomes of an otherwise mild traumatic brain injury. Among the options patients and families research is hyperbaric oxygen therapy for post-concussion syndrome, a pressurized-oxygen treatment already used at Humanaut Health for other indications. This article focuses specifically on persistent post-concussion syndrome after a single mild injury, which is a narrower question than hyperbaric oxygen therapy's use across traumatic brain injury more broadly (a topic covered in a separate, more general article on HBOT and TBI).

Before going further, one fact needs to be stated plainly: HBOT is not an FDA-cleared treatment for post-concussion syndrome, and the clinical trial evidence on whether it helps is genuinely mixed, not settled in either direction.

What Is Post-Concussion Syndrome?

Post-concussion syndrome describes a cluster of symptoms, headache, dizziness, cognitive and memory difficulty, sensitivity to light and noise, sleep disturbance, and mood changes, that continue well beyond the typical recovery window after a mild traumatic brain injury. Most concussions resolve within days to a few weeks. The trials discussed below generally define persistent symptoms as those lasting three months or longer as post-concussion syndrome rather than ordinary concussion recovery.

What Is Hyperbaric Oxygen Therapy and How Does It Work?

Hyperbaric oxygen therapy is a pressurized oxygen treatment delivered inside a sealed chamber, where increased atmospheric pressure allows the body to absorb substantially more oxygen than normal breathing provides at sea level. The proposed, though not conclusively proven, mechanism for brain-related use is that higher oxygen delivery at the tissue level may support cellular repair processes and help regulate inflammation in injured tissue. At Humanaut Health, HBOT sessions follow a five-step process: entering the pressurized chamber, increased oxygen absorption into the bloodstream, deeper tissue penetration, cellular repair support, and inflammation reduction through improved circulation, delivered by trained clinical staff at the clinic.

Is Hyperbaric Oxygen Therapy FDA-Approved for Post-Concussion Syndrome?

No. The U.S. Food and Drug Administration has cleared hyperbaric oxygen therapy for a narrow, specific list of indications: decompression sickness, air or gas embolism, carbon monoxide poisoning, certain problem wound healing including diabetic foot ulcers, some radiation injury, severe anemia, gas gangrene, crush injury, compromised skin grafts or flaps, and sudden sensorineural hearing loss. HBOT use for post-concussion syndrome does not appear on this list. Any use of HBOT for post-concussion syndrome is considered investigational, which matters for how the research below should be read: strong individual results would still describe an off-label, evolving area of medicine rather than an established standard of care.

What Does the Research Actually Show?

The clinical trial picture here is a genuine split, and a fair discussion needs to represent both sides rather than lead with the most encouraging result.

Trials Finding No Benefit Over Sham

The two most methodologically rigorous studies in this specific population found no advantage for HBOT. A three-arm, double-blind, sham-controlled trial in active-duty service members with persistent post-concussion symptoms compared routine care alone, routine care plus HBOT at 1.5 atmospheres, and routine care plus a sham chamber session at 1.2 atmospheres (Miller et al., JAMA Internal Medicine, 2015). Both chamber groups improved relative to routine care alone, but there was no significant difference between the HBOT group and the sham group, leading the authors to conclude the improvement was likely not oxygen-mediated. A separate sham-controlled trial in Marines with blast-related post-concussion syndrome, using three blinded arms including two different oxygen pressures, found no significant benefit of HBOT over sham on a validated symptom questionnaire at three months, in any subgroup (Cifu et al., Annals of Neurology, 2014).

Trials Finding a Possible Benefit

Other trials point the other way, though each carries a meaningful caveat. A randomized trial without a true sham-pressure control found significant cognitive and quality-of-life improvement in civilians who had lived with post-concussion syndrome for one to five years, compared with a delayed-treatment control period (Boussi-Gross et al., PLoS ONE, 2013) — a positive result, but the absence of a sham-pressure arm means placebo or attention effects cannot be ruled out. A more recent sham-controlled trial reported a statistically significant benefit at thirteen weeks, though it enrolled fewer than a third of its target sample size and had substantial attrition, which limits how much weight the result can carry (Weaver et al., Scientific Reports, 2025). A small sham-controlled trial in children aged eight to fifteen with persistent symptoms found improved cognitive and behavioral function with HBOT compared with sham, though the sample size was limited (Hadanny et al., Scientific Reports, 2022). And a crossover trial without a sham-pressure control reported a large reduction in symptoms with HBOT, but the control group showed a nearly identical improvement once it crossed over to active treatment (Harch et al., Medical Gas Research, 2020), a pattern consistent with either a genuine delayed effect or a non-specific response that only a sham arm could distinguish.

Why the Research Is So Mixed

Part of the disagreement traces back to how "sham" is defined in these trials. One perspective argues that commonly used sham conditions still expose participants to increased ambient pressure, which may itself be biologically active and could mask a true treatment effect, with a related re-analysis proposing that a specific lower-pressure protocol may be the more consistently effective "dose" Harch, Frontiers in Neurology, 2022. Both of these come from the same author who also conducted one of the positive, non-sham-controlled trials above, so they are worth treating as one contested viewpoint in an ongoing methodological debate, not as evidence that overturns the negative sham-controlled trials.

What Do Medical and Regulatory Authorities Say?

No major medical society currently recommends hyperbaric oxygen therapy as a standard or first-line treatment for post-concussion syndrome. A Cochrane systematic review registered specifically to answer this question has not yet been completed; only the 2017 study protocol exists (Tsutsumi et al., Cochrane Database of Systematic Reviews, 2017), which itself estimated that over a thousand participants per study arm would be needed to detect a reliable effect — a sign of how modest any true benefit is likely to be. A 2016 U.S. Government Accountability Office report reviewing Department of Defense and Veterans Affairs-funded HBOT research for traumatic brain injury found the evidence inconclusive and documented continued federal investment in further controlled trials rather than adoption of HBOT as standard military or VA care. Taken together, this is a field where research continues, but no governing body has endorsed HBOT as a proven or standard way to manage persistent post-concussion symptoms.

How Does HBOT Compare With Standard Post-Concussion Syndrome Management?

The evidence-backed foundation of post-concussion syndrome care remains graded return to normal activity, vestibular and vision therapy, cognitive strategies, sleep and headache management, and a gradual, supervised return to exercise. Most people improve over time with this approach, though a minority have a more prolonged course. Where HBOT is being considered, it is reasonable to think of it as a potential adjunct explored under physician guidance alongside these standard approaches, not a replacement for them, and not a guaranteed path to symptom resolution. Because post-concussion symptoms can overlap with other treatable issues, such as sleep disorders, hormonal shifts, or nutritional deficiencies, a comprehensive diagnostic workup like an Advanced Health Check can help identify and rule out other contributing causes before adding any adjunctive therapy to the plan.

Is Hyperbaric Oxygen Therapy Safe?

Across the sham-controlled trials reviewed here, the most commonly reported HBOT-related adverse event was middle-ear barotrauma, a pressure-related discomfort or injury to the ear; serious adverse events were uncommon. As with any pressurized therapy, individualized medical evaluation and candidacy screening matter, and safety data from these trials should not be read as an endorsement of effectiveness, only as a generally reassuring picture of tolerability.

Hyperbaric Oxygen Therapy Post-Concussion Syndrome Management: What to Expect

Study protocols in this area have varied, but adult trials commonly used around 40 sessions delivered over 10 to 12 weeks, with pediatric and other protocols differing somewhat. Anyone considering HBOT for persistent post-concussion symptoms should expect an individualized, physician-guided plan rather than a fixed, one-size-fits-all course, and realistic expectations given the mixed evidence above, not an assumption that symptoms will fully resolve. For patients already working through a broader recovery and optimization plan, Humanaut Health also offers complementary regenerative therapies like stem cell therapy as part of its overall care model; these are separate services and are not a treatment for post-concussion syndrome itself.

Frequently Asked Questions

Does hyperbaric oxygen therapy help post-concussion syndrome?

The evidence is mixed. Some sham-controlled trials found a benefit over sham, while two of the largest and most rigorously controlled trials in this exact population found no benefit at all.

Is HBOT for post-concussion syndrome FDA-approved?

No. Post-concussion syndrome is not among hyperbaric oxygen therapy's FDA-cleared indications, which cover a different, specific set of conditions.

How is post-concussion syndrome different from a traumatic brain injury more broadly?

Post-concussion syndrome refers specifically to persistent symptoms after a single mild traumatic brain injury. A separate article on this site discusses hyperbaric oxygen therapy across the broader and often more severe traumatic brain injury population.

How many HBOT sessions have been studied for post-concussion syndrome?

Protocols vary, but adult trials have commonly used around 40 sessions delivered over 10 to 12 weeks, with treatment plans individualized and physician-guided.

Why do HBOT studies on post-concussion syndrome disagree with each other?

Much of the disagreement centers on what counts as an adequate "sham" control for a pressurized-gas therapy, along with ongoing debate over whether pressure "dose" affects outcomes, both unresolved methodological questions.

What are the risks or side effects of hyperbaric oxygen therapy?

Middle-ear barotrauma was the most commonly reported side effect across the trials reviewed here, and serious adverse events were uncommon.

What does hyperbaric oxygen therapy post-concussion syndrome management look like in practice?

It typically involves a defined course of sessions under physician guidance, alongside standard post-concussion care, with outcomes that should be viewed as uncertain rather than guaranteed given the mixed trial evidence.

What is the standard treatment for post-concussion syndrome?

Graded return to activity, vestibular and vision therapy, cognitive strategies, and sleep and headache management form the evidence-backed foundation, with most people improving over time.

Key Takeaways

• Post-concussion syndrome is a persistent symptom cluster following mild traumatic brain injury, distinct from the broader traumatic brain injury population.
• Hyperbaric oxygen therapy for post-concussion syndrome is not an FDA-cleared use, and any application remains investigational.
• Clinical trial evidence is genuinely split: two of the most rigorous sham-controlled trials found no benefit, while several other trials, each with design limitations, reported improvement.
• No major medical society or completed Cochrane review currently endorses HBOT as standard post-concussion syndrome care.
• Standard, evidence-backed management remains the foundation of recovery, with HBOT best framed as a possible physician-guided adjunct, not a replacement.

If you are exploring options for lingering post-concussion symptoms, speak with Humanaut Health's clinical team about hyperbaric oxygen therapy to discuss whether it may be appropriate as part of your broader care plan.

Sources

• Miller RS et al., JAMA Internal Medicine, 2015
• Cifu DX et al., Annals of Neurology, 2014
• Boussi-Gross R et al., PLoS ONE, 2013
• Weaver LK et al., Scientific Reports, 2025
• Hadanny A et al., Scientific Reports, 2022
• Harch PG et al., Medical Gas Research, 2020
• Harch PG, Frontiers in Neurology, 2022
• Harch PG, Contemporary Clinical Trials Communications, 2024
• Tsutsumi Y et al., Cochrane Database of Systematic Reviews, 2017
• U.S. Government Accountability Office, GAO-16-154, 2016